Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cediranib + pemetrexed
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cediranib + pemetrexed is an investigational combination therapy evaluated primarily in malignant pleural mesothelioma and non-small cell lung cancer. Cediranib is a potent oral small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR), as well as platelet-derived growth factor receptor (PDGFR) and c-Kit, targeting tumor angiogenesis. Pemetrexed is an antifolate chemotherapy agent that inhibits multiple folate-dependent enzymes involved in purine and pyrimidine synthesis, disrupting tumor cell proliferation. The combination aims to enhance antitumor efficacy by combining cytotoxic and antiangiogenic mechanisms, and has been studied both as a doublet and as part of triplet regimens (with cisplatin), mainly for use in unresectable, chemotherapy-naïve malignancies such as malignant pleural mesothelioma[1][2][3][5].
- Brand names
- RecentinAlimta
- Other names
- cediranib maleate + pemetrexed disodium
02
Targets
GART (GAR transformylase)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)DHFR (Dihydrofolate reductase)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)TS (Thymidylate synthase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on cediranib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cediranib + pemetrexed.